ClinicalTrials.gg
CompletedNCT00644670Updated Feb 18, 2021

A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol

A Phase 4 interventional study of Atorvastatin and Atorvastatin in Dyslipidemias, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 17 sites in Belgium. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Enrollment
21st of 47
232 · median 165
Started
2003
with 5 others
Phase 4
22 of 47
1 open now
Registered
13th of 47
by date
Lead sponsor
9 of 47
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 21st largest by enrollment, is one of 6 that started in 2003, is one of 22 in phase 4, and was the 13th registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effectiveness of atorvastatin in lowering cholesterol and getting these high risk patients to their goals of LDL \<115 mg/dl across starting doses of 10 mg, 20 mg, or 40 mg with one step titration.

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dyslipidemia
  • At a high risk for coronary heart disease

Exclusion criteria

Exclusion Criteria:

  • Use of higher than usual maintenance doses of statin drugs at screening
  • Uncontrolled diabetes or high blood pressure
  • Impaired liver function
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
232 participants (actual)

Study arms

  • Experimental
    Previous Treatment with a Usual Maintenance Dose of a Statin

    Drug: Atorvastatin

  • Experimental
    Statin-Naive

    Drug: Atorvastatin

Interventions

  • In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.

  • In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects in entire group who achieved low-density lipoprotein cholesterol (LDL-C) target of <115 mg/dL

    Time frame: Week 12

Secondary outcomes

  1. Mean percent change from baseline in LDL-C, high-density lipoprotein cholesterol (HDL-C), non-HDL-C (triglycerides of >200 mg/dL), total cholesterol, triglycerides, and apolipoprotein B for statin-naive patients

    Time frame: Weeks 6 and 12

  2. Proportion of subjects across different LDL-C strata who achieved LDL-C target

    Time frame: Week 6

  3. Proportion of diabetic subjects in entire group who achieved LDL-C target

    Time frame: Week 12

  4. Proportion of subject on statin therapy at baseline who achieved LDL-C target and total cholesterol target (<190 mg/dL)

    Time frame: Week 12

  5. Change from baseline in hemoglobin A1c levels

    Time frame: Week 12

  6. Adverse events and laboratory test changes

    Time frame: Weeks 6 and 12

  7. Proportion of subjects in entire group who achieved LDL-C target

    Time frame: Week 6

07

Study locations

17 sites
  • Pfizer Investigational Site
    Antwerpen, 2018, Belgium
  • Pfizer Investigational Site
    Brasschaat, 2930, Belgium
  • Pfizer Investigational Site
    Brussels, 1180, Belgium
  • Pfizer Investigational Site
    Edegem, 2650, Belgium
  • Pfizer Investigational Site
    Genk, B-3600, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Gilly (charleroi), 6060, Belgium
  • Pfizer Investigational Site
    La Louvière, 7100, Belgium
  • Pfizer Investigational Site
    Liège, 4000, Belgium
  • Pfizer Investigational Site
    Mechelen, 2800, Belgium
  • Pfizer Investigational Site
    Menen, 8930, Belgium
  • Pfizer Investigational Site
    Merksem, 2170, Belgium
  • Pfizer Investigational Site
    Mortsel, 2640, Belgium
  • Pfizer Investigational Site
    Roeselare, 8800, Belgium
  • Pfizer Investigational Site
    Seraing, 4100, Belgium
  • Pfizer Investigational Site
    Wilrijk, 2610, Belgium
  • Pfizer Investigational Site
    Wingene, 8750, Belgium
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2008
First posted
Mar 27, 2008
Start
Jun 2003
CompletionActual
Mar 2004
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00644670
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Jun 2003
Completion
Mar 2004
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion